Viewing nowCombinationJanugriptin Duo Tablet 50/850 milligrams
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Searose Pharmaceuticals Co., Ltd.

MFDS item code 202300836 · Approved 2023.03.13 · Insurance code 689001810
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps effectively control blood sugar levels when used alongside diet regulation and exercise therapy in patients with type 2 diabetes. The combination of sitagliptin and metformin works together to improve blood sugar levels. Therefore, this medication is suitable for individuals for whom diet and exercise alone are insufficient, playing an important role in blood sugar management. Continuous treatment and improvements in lifestyle habits while taking this medication can yield even better outcomes. This medication improves blood sugar control in patients with type 2 diabetes.
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Use This Medicine). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral hypoglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may affect blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Use This Medicine).
This medication is used in the treatment of diabetes and contains the active ingredients sitagliptin and metformin. Firstly, allergic reactions may occur during the use of this medication, so if symptoms such as skin rash, hives, or difficulty breathing appear, you should immediately stop taking it and go to a hospital. Additionally, severe side effects such as pancreatitis (inflammation of the pancreas) have been reported, so if you experience abdominal pain, vomiting, or severe abdominal discomfort, you should consult a doctor immediately. The metformin component in this medication can cause a serious metabolic disorder called lactic acidosis, so if symptoms such as sudden difficulty breathing, muscle pain, fatigue, or abdominal pain occur, you should inform medical personnel immediately. This medication should not be taken by individuals with impaired kidney function, severe infections, or dehydration. Also, patients with acute heart problems or severe heart failure should not take this medication. You should stop taking this medication before examinations using iodinated contrast agents and should not resume until kidney function is confirmed to be normal after the examination. Women who are pregnant or breastfeeding should also not take this medication. This medication can cause hypoglycemia, so caution is needed if meals are skipped or are irregular, or during intense exercise. Furthermore, the risk of hypoglycemia increases when taken with other antidiabetic drugs or insulin; thus, medication dosage should be adjusted according to a doctor's instructions. This medication is not recommended for patients with poor liver function, and regular monitoring of kidney function and blood tests should be conducted during use. Alcohol consumption can increase the risk of lactic acidosis; therefore, it is advisable to avoid alcohol while taking this medication. It may be necessary to discontinue taking this medication for a period before and after surgery, and once the patient’s condition is stabilized, treatment can be resumed. During the use of this medication, regular checks of blood sugar, kidney function, and vitamin B12 levels should be conducted to ensure there are no abnormalities. Finally, this medication has not been established as safe and effective for children, and elderly patients should take caution with impaired kidney function.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air intrusion, and it is recommended to store it at room temperature between 1 degree and 30 degrees Celsius. This helps ensure the medication’s effectiveness is maintained over a longer period and prevents degradation.
Pink oval film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Searose Pharmaceuticals Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.